Cogent Biosciences, Inc. - Common Stock (COGT)

Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from its SUMMIT clinical trial for bezuclastinib. This investigational drug, aimed at non-advanced systemic mastocytosis (NonAdvSM), demonstrated significant efficacy and a favorable

According to the technical analysis of over 4,400 firms with a market cap exceeding $100 million, three firms are in the overbought zone.

Cogent Biosciences' SUMMIT trial shows bezuclastinib improves symptoms and quality of life in systemic mastocytosis, with favorable safety data.

Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.

U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed.

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Cogent reported positive SUMMIT trial data for bezuclastinib in NonAdvSM and plans to file for FDA approval by late 2025.

COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the second quarter of 2024.

COGT stock results show that Cogent Biosciences missed analyst estimates for earnings per share the first quarter of 2024.

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.